Sakamoto M, Sakamoto H, Suehiro Y, Akiya T, Iwabuchi H, Sakunaga H, Muroya T, Noda T, Sugishita T, Tenjin Y
Department of Gynecology, Sasaki Institute Kyoundo Hospital.
Nihon Rinsho. 1996 Apr;54(4):933-43.
Comparative Genomic Hybridization (CGH) is a powerful new method which allows genome-wide mapping of regions with DNA sequence copy number changes (both increases and decreases) in a single experiment without previous knowledge of the locations of the regions of abnormality. CGH is based on in situ hybridization of differentially labeled total genomic tumor DNA and normal DNA to normal human metaphase chromosomes. After hybridization copy number variations among the sequences in the tumor DNA are detected by measuring the tumor/normal fluorescence intensity ratio for each locus in the target chromosomes. Many previously unknown chromosomal regions with relative copy number changes have been detected in various tumors by CGH. Some changes have been identified as genetic markers associated with biological and clinico-pathological characteristics (i.e., histopathological grade, and clinical outcome). We review the published CGH articles and discuss briefly on current progress in CGH analysis to ovarian and uterine cervical cancer in our laboratory.
比较基因组杂交（CGH）是一种强大的新方法，它能够在一次实验中对全基因组范围内存在DNA序列拷贝数变化（增加和减少）的区域进行定位，而无需事先了解异常区域的位置。CGH基于将差异标记的肿瘤全基因组DNA和正常DNA与正常人中期染色体进行原位杂交。杂交后，通过测量目标染色体上每个位点的肿瘤/正常荧光强度比来检测肿瘤DNA中序列间的拷贝数变异。通过CGH已在各种肿瘤中检测到许多先前未知的具有相对拷贝数变化的染色体区域。一些变化已被确定为与生物学和临床病理特征（即组织病理学分级和临床结果）相关的遗传标记。我们回顾已发表的CGH文章，并简要讨论我们实验室在CGH分析卵巢癌和子宫颈癌方面的当前进展。
